Greece becomes a center of production of raw materials and medicines in Europe, thus declaring independence in raw materials from third countries.
The production of 20% of the injectable products that Europe needs in Greece will take place in Tripoli, Arcadia. It even paves the way for the production of monoclonal antibodies.
Specifically, the investment plan of the Greek pharmaceutical company Demo SA, with managing director Dimitris Demos, among others, provides for the creation of three units for the production of raw materials, as well as an additional four units for the production of final pharmaceuticals for hospitals. All will be based in Arcadia.
In addition, in terms of research and development, the company has already created new modern laboratories in Thessaloniki. The new laboratories of the company in Thessaloniki are intended for research needs, have an area of 2,500 sq.m. and will employ over 100 people from various disciplines.
With these investments, in Tripoli and Northern Greece, Demo proceeds to the production of 125 new hospital drugs, while it will cover 20% of the needs of the whole of Europe.
And monoclonal antibodies
A major investment is the creation of a standard monoclonal antibody development unit. The investment will be made in Agios Stefanos, Attica and will take into account another important sector, that of education and employment.
“DEMO’s investment will put our country in the” closed league “of the 15 countries active in this field worldwide and will contribute to the employment of highly educated executives, who so far are employed in academia or in foreign companies,” said Mr. Demos , at an event at the Stavros Niarchos Foundation Cultural Center.
Sofia Kostara
.
Source From: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
